drugset / Trial / NCT07369336

Clinical Outcomes of Inhaled Amikacin in Ventilator Associated Pneumonia

NCT07369336

Phase 4 Completed 90 enrolled Postgraduate Medical Institute, Lahore
RandomizedParallel-groupOpen-labelTreatment

Summary

Article: Clinical Outcomes of Inhaled Amikacin in Ventilator-Associated Pneumonia: A group randomized controlled,add-on trial English:Patients in intensive care units often need ventilators to breathe. Sadly, these machines sometimes cause serious lung infections, known as ventilator-associated pneumonia (VAP). This study tested whether giving the antibiotic amikacin by inhalation (so itgoes straight into the lungs) could improve recovery when added to regular treatment. Researchers looked at how quickly infections cleared, how long patients needed the ventilator, and whether hospital stays were shortened. They also monitored for side effects.

Timeline

Start
2024-01-05
Primary completion
2024-11-25
Completion
2025-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Amikacin Small molecule 20 mg/kg Other

Indications